Login to Your Account



Pharma: Other News To Note


Wednesday, August 22, 2012
• GE Healthcare, of Princeton, N.J., said the label for contrast agent Optison (perflutren protein-Type A microspheres injectable suspension, USP) was updated to include warnings about serious cardiopulmonary reactions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription